Parkinson's Disease

Bi
Illustration of author Rachel Reid at her desk, announcing delay of 'Unrivaled' book due to Parkinson's, with calendar, novels, and Instagram phone.
Hoton da AI ya samar

Rachel Reid delays Unrivaled book to June 2027 for health reasons

An Ruwaito ta hanyar AI Hoton da AI ya samar

Author Rachel Reid has postponed the release of her novel Unrivaled from September 2026 to June 1, 2027, citing worsening Parkinson's symptoms and demands from recent fame. The book is the seventh in her Game Changers series and the third focused on hockey rivals Shane Hollander and Ilya Rozanov. Reid announced the delay in an Instagram video, emphasizing her commitment to quality.

People with Parkinson's disease experience reduced enjoyment from pleasant smells like lemon, according to a new study. This difference in smell perception could help diagnose the condition earlier and more simply. Researchers found that brain processing of scents varies in those affected, distinguishing them from others with smell loss.

An Ruwaito ta hanyar AI

Author Rachel Reid has postponed the publication of her upcoming book 'Unrivaled' from September 2026 to June 1, 2027, citing worsening Parkinson's symptoms and a busy schedule following the success of the 'Heated Rivalry' TV adaptation. The novel is the seventh in her 'Game Changers' series and the third focused on characters Shane Hollander and Ilya Rozanov. Reid shared the news in an Instagram video on February 24, 2026, assuring fans the delay will result in a better book.

Scientists have identified a key cellular regulator called PP2A-B55alpha that balances mitochondrial health, potentially leading to new therapies for Parkinson's disease. In preclinical models, reducing its activity improved motor symptoms and mitochondrial function. The findings, published in Science Advances, could extend to other mitochondrial disorders and cancer.

An Ruwaito ta hanyar AI

Scientists have developed a blood-based test that detects Parkinson's disease up to seven years before the onset of symptoms. The test targets abnormal alpha-synuclein proteins and shows high accuracy in at-risk individuals. This breakthrough could enable earlier treatments to slow disease progression.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi